FDA Clears The Way For Arrowhead Research Corp (NASDAQ:ARWR) Hep B Treatment, With A Caveat

Arrowhead Research Corp (NASDAQ:ARWR) has finally been given the go ahead sign to beggin its phase II B trials of ARC 520. The company will now be able to further its research on the Hepatitis B treatment courtesy of the FDA. Despite the approval, the company still has to persuade other supervisory bodies before it […]

Buzzing Stocks: Energy Transfer Equity LP (NYSE:ETE), Abraxas Petroleum Corp. (NASDAQ:AXAS), Arrowhead Research Corp (NASDAQ:ARWR)

Boston, MA 10/16/2014 (wallstreetpr) – Energy Transfer Equity LP (NYSE:ETE) saw its stock post a healthy 9.2 percent upward rally during trading on 15th October. The stock was trading at $52.25 per share at day’s closing. The big surge was accomplished on the back of upgrade the stock was awarded by analysts at Robert W. […]

Arrowhead Research Corp (NASDAQ:ARWR)’s ARC-520 Data Disappoints

Boston, MA 10/09/2014 (wallstreetpr) – Arrowhead Research Corp (NASDAQ:ARWR) experimental hepatitis B therapy data disappointed the investors following which the stocks of Arrowhead plummeted more than 40%. In the phase II study conducted, the experimental drug ARC-520 resulted in a 0.3 log reduction in HBsAG when dosed at 2 mg/kg. HBsAG indicates the presence of […]

Buzzing Stocks: A10 Networks Inc (NYSE:ATEN), Arrowhead Research Corp (NASDAQ:ARWR), Pendrell Corp (NASDAQ:PCO)

Boston, MA 10/09/2014 (wallstreetpr) – Application networking solutions provider A10 Networks Inc (NYSE:ATEN) has warned that its third quarter revenue would be much lower than it had previously anticipated. The warnings came when the company declared its preliminary third quarter operation results for period ending 30th September. It anticipates worldwide revenue for 3Q to come […]

Top Losers: Arrowhead Research Corp (NASDAQ:ARWR), A10 Networks Inc (NYSE:ATEN), Liquid Holdings Group Inc (NASDAQ:LIQD)

Boston, MA 10/09/2014 (wallstreetpr) – Bio-pharmaceutical firm Arrowhead Research Corp (NASDAQ:ARWR) showcased much awaited data and results it has generated from its Phase 2 clinical study of drug candidate ARC-520 on 8th October. The disappointing data crashed the price of the company stock by nearly 43.8 percent. The drug maker indicated that it would be […]

Shareholders Update: Zulily Inc (NASDAQ:ZU), Maxwell Technologies Inc. (NASDAQ:MXWL), Arrowhead Research Corp (NASDAQ:ARWR)

Boston, MA 04/02/2014 (wallstreetpr) – The traction in the e-commerce and discount sales business is having its positive impact on Zulily Inc (NASDAQ:ZU) as it is in many other online sales platform stocks. Having come to the scene just last year, Zulily has quickly become a leading provider of flash sales in North America. Its multi-pronged […]

Arrowhead Research Corp (NASDAQ:ARWR) Hits a Five Year High

Boston, MA 03/06/2014 (wallstreetpr) – Arrowhead Research Corp (NASDAQ:ARWR) which is a nanomedicine company that develops RNAI-based therapeutic products hit a five year high on Tuesday after a massive exchange of its shares. Arrowhead surged by highs of 29% after RBC Capital analysts Michael Yee and Deutsche bank initiated coverage of the company’s stock. RBC […]

Why Arrowhead Research Corp (NASDAQ:ARWR) Is Going Up

Boston, MA 03/05/2014 (wallstreetpr) – Arrowhead Research Corp (NASDAQ:ARWR) shares are soaring; a rally that started in pre-market trading has been sustained in the regular session. Already the shares have set a new high for the year which is also the new 12 months high for the stock. As usual, there must be something behind […]

Arrowhead Research Corp (NASDAQ:ARWR) stock up 18.5%

Boston, MA 10/01/2013 (wallstreetpr) – Arrowhead Research Corp (NASDAQ:ARWR) has staged a remarkable rally on the browsers last week. It gained more than 18.5% in the week. It shed some of the gains during trading on September 30. It slid by close to 5.59% from its September 27 closing price of $6.05. In spite of the […]